Detection and management of comorbidity in patients with schizophrenia (Q35102472)

6 August 2017

1 reference

title

Detection and management of comorbidity in patients with schizophrenia (English)

1 reference

6 August 2017

1 reference

1 reference

Alan I Green

1

1 reference

6 August 2017

Carla M Canuso

series ordinal

2

1 reference

6 August 2017

Mark J Brenner

series ordinal

3

1 reference

6 August 2017

Joanne D Wojcik

series ordinal

4

1 reference

6 August 2017

publication date

1 March 2003

1 reference

Psychiatric Clinics of North America

6 August 2017

published in

1 reference

6 August 2017

volume

26

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

115-139

1 reference

Mortality among patients with schizophrenia

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Concurrent medical illness in the schizophrenic patient. Epidemiology, diagnosis, and management

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Occurrence and clinical correlates of psychiatric comorbidity in patients with psychotic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

The association of medical comorbidity in schizophrenia with poor physical and mental health

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Hierarchical diagnosis in chronic schizophrenia: a clinical study of co-occurring syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Excess mortality of schizophrenia. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

High rates of schizophrenia in adults with velo-cardio-facial syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Chromosomal mapping of the human catechol-O-methyltransferase gene to 22q11.1----q11.2

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

The current status of the dopamine hypothesis of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine?

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Causes of death associated with psychiatric illness

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Schizophrenia and rheumatoid arthritis: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

The prognostic significance of obsessive-compulsive symptoms in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Postpsychotic depression in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Relationships among negative, positive, and depressive symptoms in schizophrenia and psychotic depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Depression in first-episode schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Cognitive approach to depression and suicidal thinking in psychosis. 1. Ontogeny of post-psychotic depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Diagnosis of secondary depression in schizophrenia: implications for DSM-IV.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Development and Prediction of Postpsychotic Depression in Neuroleptic-Treated Schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Suicide among schizophrenics: a comparison of attempters and completed suicides

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Cognitive approach to depression and suicidal thinking in psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Depression in schizophrenia: perspective in the era of "Atypical" antipsychotic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Life events and schizophrenia. I. Comparison of schizophrenics with a community sample

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

The frequency of associations between positive and negative symptoms and dysphoria in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Depressive symptoms in schizophrenia: comprehensive differential diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Postpsychotic depression and negative symptoms: an investigation of syndromal overlap

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Prevalence and background factors of depression in first admitted schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Adjunctive imipramine in the treatment of postpsychotic depression. A controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Pharmacotherapy of impaired affect in recovering schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

A comparative study of sertraline versus imipramine in postpsychotic depressive disorder of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Obsessive-compulsive disorder in patients with schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Obsessive-compulsive disorder in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Obsessive and compulsive symptoms in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

The clinical significance of obsessions in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Clinical and neuropsychological profiles of obsessive-compulsive schizophrenia: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Obsessive and Compulsive Symptoms in Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Obsessions and Compulsions as a Distinct Cluster of Symptoms in Schizophrenia: A Neuropsychological Study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Cognitive frontal lobe dysfunction in obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Treatment of Obsessive-Compulsive Symptoms in Schizophrenic Patients With Clomipramine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Risperidone, serotonergic mechanisms, and obsessive-compulsive symptoms in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Clozapine and paroxetine in the treatment of schizophrenia with obsessive-compulsive features

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Cognitive and behavioral therapies alone versus in combination with fluvoxamine in the treatment of obsessive compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Prevalence of substance abuse in schizophrenia: demographic and clinical correlates.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Prevalence of smoking among psychiatric outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Schizophrenia and substance abuse.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Effects of substance abuse on housing stability of homeless mentally Ill persons in supported housing

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Acute effects of drug abuse in schizophrenic patients: clinical observations and patients' self-reports

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Alcohol abuse in chronic schizophrenics: implications for management in the community

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Cannabis affects the severity of schizophrenic symptoms: results of a clinical survey

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Persons with dual diagnoses of substance abuse and major mental illness: their excess costs of psychiatric care

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Pharmacological treatment of substance-abusing schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Attentional impairments in deficit and nondeficit forms of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: role of 5-HT2 receptor and alpha 1-adrenoceptor antagonism [corrected]

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

A neurobiological basis for substance abuse comorbidity in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Effect of spontaneous ingestion of ethanol on brain dopamine metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Reinforcing properties of cocaine in the medical prefrontal cortex: primary action on presynaptic dopaminergic terminals

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Treating substance abuse among patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Implementing dual diagnosis services for clients with severe mental illness

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Psychosocial approaches to dual diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Pharmacotherapy of schizophrenia patients with comorbid substance abuse

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Decreased substance use in chronically psychotic patients treated with clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Clozapine decreases smoking in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Outpatient treatment of patients with substance abuse and coexisting psychiatric disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Naltrexone augmentation of neuroleptics in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

The Iowa record-linkage study. I. Suicides and accidental deaths among psychiatric patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Case register study of suicide risk in mental disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Risk for suicide in schizophrenia and other psychotic and nonpsychotic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Suicide among schizophrenics: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Suicidal behavior in schizophrenia and its relationship to awareness of illness

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Risk factors for suicide in psychiatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Risk factors for suicide in patients with schizophrenia: Nested case–control study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Depression, hopelessness and suicide in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Factors Associated With Suicide Attempts Among Patients With Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Suicide and schizophrenia: a nationwide psychological autopsy study on age- and sex-specific clinical characteristics of 92 suicide victims with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Symptoms, subtype, and suicidality in patients with schizophrenia spectrum disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Schizophrenia: a life-shortening disease

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Management of the suicidal patient with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Suicide victims with schizophrenia in different treatment phases and adequacy of antipsychotic medication.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Morbidity and Rate of Undiagnosed Physical Illnesses in a Psychiatric Clinic Population

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

The schizophrenic patient in the somatic hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Mortality in schizophrenia. A ten-year follow-up based on the Stockholm County inpatient register

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Polydipsia and water intoxication in psychiatric patients: a review of the epidemiological literature

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Osteoporosis demonstrated by dual energy x-ray absorptiometry in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Causes of the excess mortality of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Causes of death in DSM-III schizophrenics and other psychotics (atypical group). A comparison with the general population

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Mortality and causes of death in schizophrenic patients in Denmark

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Morbidity risks of schizophrenia and affective disorders among first degree relatives of patients with schizophrenia, mania, depression and surgical conditions

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Physical health and illness in a psychiatric outpatient department population.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Pain insensitivity in schizophrenia: a neglected phenomenon and some implications

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

The unhealthy lifestyle of people with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Socioeconomic status and health: how education, income, and occupation contribute to risk factors for cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Incidence of cancer among persons with schizophrenia and their relatives

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Schizophrenia and cancer: is there a need to invoke a protective gene?

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Haloperidol increases smoking in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Alcohol & drug abuse: a preliminary investigation of cocaine craving among persons with and without schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Schizophrenia and HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

The distribution of body mass index among individuals with and without schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

The distribution of adipose tissue in female in-patients receiving psychotropic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Weight gain from novel antipsychotic drugs: need for action

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Novel antipsychotics and new onset diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Olanzapine increases weight and serum triglyceride levels.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Clozapine-related seizures

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Myocarditis and cardiomyopathy associated with clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Myocarditis and cardiomyopathy associated with clozapine use in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Neuroleptic-induced hyperprolactinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Galactorrhea and hyperprolactinemia in schizophrenic patients on neuroleptics: frequency and etiology

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Can estradiol modulate schizophrenic symptomatology?

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

1 reference

7 January 2021

Relationship of gender and menstrual status to symptoms and medication side effects in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Estradiol levels in psychotic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Olanzapine use in women with antipsychotic-induced hyperprolactinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Body weight gain induced by antipsychotic drugs: mechanisms and management

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Weight gain associated with neuroleptic medication: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Diabetes mellitus in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Prevalence and correlates of diabetes in national schizophrenia samples.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

The apparent effects of ziprasidone on plasma lipids and glucose.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Reinforcement and weight loss in schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Cognitive behavior therapy for weight gain

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

A program for treating olanzapine-related weight gain

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

Effect of amantadine on weight gain during olanzapine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900014-X

7 January 2021

10.1016/S0193-953X(02)00014-X

Identifiers

DOI

1 reference

6 August 2017

1 reference